Nigeria: Malaria Vaccine Less Effective Than Expected

[Vanguard] HOPES of a universal, commercially licensed malaria vaccine this year may have dimmed as the first candidate malaria vaccine to reach phase III clinical trials, though safe, has been found to provide only modest protection for infants.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news

Related Links:

Abstract Analysis of the Amino-peptidase N (APN) protein from Anopheles culicifacies as a vector based Transmission Blocking Vaccines (TBV) target has been considered for malaria vaccine development. Short peptides as potential epitopes for B cells and cytotoxic T cells and/or helper T cells were identified using prediction models provided by NetCTL and IEDB servers. Antigenicity determination, allergenicity, immunogenicity, epitope conservancy analysis, atomic interaction with HLA allele specific structure models and population coverage were investigated in this study. The analysis of the target protein helped to...
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
(University of Bern) An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the Ume å University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment. The researchers were able to identify hundreds of targets that are urgently needed in drug and vaccine development to eradicate the disease.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
(Deakin University) Researchers have narrowed down the malaria proteins and disease-fighting antibodies that could be used to develop a vaccine against the most severe forms of malaria.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract Malaria is a disease of public health importance in many parts of the world. Currently, there is no effective way to eradicate malaria, so developing safe, efficient, and cost-effective vaccines against this disease remains an important goal. Current research on malaria vaccines is focused on developing vaccines against pre-erythrocytic stage parasites and blood-stage parasites or on developing a transmission-blocking vaccine. Here, we briefly describe the progress made towards a vaccine against Plasmodium falciparum, the most pathogenic of the malaria parasite species to infect humans. PMID: 3168740...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Control and elimination of malaria can be accelerated by transmission-blocking interventions such as vaccines. A surface antigen of Plasmodium falciparum gametocytes, Pfs230, is a leading vaccine target antigen, ...
Source: Malaria Journal - Category: Infectious Diseases Authors: Tags: Research Source Type: research
CONCLUSIONS: The safety profile of RTS,S/AS01 in HIV-infected children was comparable to that of the comparator (meningococcal or rabies) vaccines. RTS,S/AS01 was immunogenic in HIV-infected children but antibody concentrations were lower than in children with an unknown or negative HIV status. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT00866619. PMID: 31708182 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Plasmodium vivax, the chronic relapsing human malaria parasite with the most widespread distribution, possesses proteins associated with the merozoite surface that could be targets for host immune responses and potential vaccine candidates. Of these, the merozoite surface protein 3 of P. vivax (PvMSP3) is an attractive vaccine target as well as a genetic marker for epidemiological surveillance. PvMSP3 comprises a group of protein members encoded by a multigene family. Although some protein members, i.e. PvMSP3α and PvMSP3β, have been targets for molecular and immunological investigations, the m...
Source: Infection, Genetics and Evolution - Category: Genetics & Stem Cells Authors: Tags: Infect Genet Evol Source Type: research
Notice NOT-AI-20-006 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
First ever cases in Britain, says Public Health England Related items fromOnMedica Vaccine linked to earlier onset of seizures in Dravet syndrome Scans show severe brain damage in Zika-affected babies Lyme disease may be three times more common in UK than previously thought Single-dose malaria drug eliminates parasite from liver Common anti-parasitic could be new tool for malaria control
Source: OnMedica Latest News - Category: UK Health Source Type: news
In this study, using samples collected from young children in Ghana at multiple time points during a longitudinal study, we adapted a predictive modelling framework which combines feature selection and machine learning techniques to identify an antigen signature of clinical immunity to malaria. Our results show that an individual's immune status can be accurately predicted by measuring antibody responses to a small defined set of 15 target antigens. We further demonstrate that the identified immune signature is highly versatile and capable of providing precise and accurate estimates of clinical protection from malaria in a...
Source: Molecular and Cellular Proteomics : MCP - Category: Molecular Biology Authors: Tags: Mol Cell Proteomics Source Type: research
More News: Clinical Trials | Infectious Diseases | Malaria | Malaria Vaccine | Vaccines